Geneva, 3 April 2020 – Disruptions caused by the COVID-19 pandemic are likely to have a devastating impact on immunisation programmes in the world’s least-developed countries, according to a new analysis by Gavi, the Vaccine Alliance. Immediate delays to vaccination campaigns and routine introductions will mean at least 13.5 million people in 13 of the world’s least-developed countries will not be protected against diseases like measles, polio and human papillomavirus (HPV), with millions more likely to follow.
The Vaccine Alliance and its partners are urgently working to keep immunisation programmes running, however at least 21 low- and middle-income countries are already reporting vaccine shortages as a result of border closures and disruptions to air travel.
So far, 14 major Gavi-supported vaccination campaigns against polio, measles, cholera, HPV, yellow fever and meningitis have been postponed, as have four national vaccine introductions. Collectively these would have immunised more than 13.5 million people. The number of people missing out on vaccines is likely to rise substantially as Gavi expects a significant proportion of planned vaccine campaigns to be postponed in the coming months, with routine immunisation programmes also severely impacted as key staff are redeployed and communities observe physical distancing.
Gavi is redirecting 10% of its funding for health systems for immediate use, until more substantial support starts to flow, towards supporting countries’ response to COVID-19. This includes support for personal protective equipment (PPE), diagnostics, training and communications campaigns. Gavi is ready to work with Alliance partners to support mass immunisation campaigns once emergency measures are lifted and, assuming successful fundraising for the 2021-25 period, help repair health systems, boost vaccine coverage rates and protect the next generation against disease in the coming years.
“The world’s poorest countries need the help of the international community more than ever to help mitigate the worst impacts of the COVID-19 pandemic and to ensure that they are not hit by an even higher death toll from preventable diseases which can further overwhelm the health systems,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance.
“Our Alliance is working hard to prepare health systems and health workers in these countries for the pandemic but we are also doing everything we can at the same time to prevent further loss of life by ensuring routine immunisations, where possible, continue and that mass vaccination campaigns take place once the immediate crisis is over. Children missing out now must not go their whole lives without protection from disease. The legacy of COVID-19 must not include the global resurgence of other killers like measles and polio.”
A Gavi analysis of Imperial College modelling suggests that without any mitigation strategies, COVID-19 could lead to 12.9 million deaths in the 73 Gavi-supported countries, compared with 0.9 million deaths if suppression measures are taken. The latter will be a huge challenge to implement in impoverished communities which cannot afford long periods at home.
In addition to Gavi’s immediate support for health systems in the countries where it is active, Gavi is also helping the development of COVID-19 vaccine candidates, as well as supporting efforts to manufacture, purchase and deliver vaccines to those who need them once they are available.
On Monday 30 March the WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization recommended that all one-off preventive vaccination campaigns should cease as countries focus on a COVID-19 response, however routine immunisation should continue where possible. The Global Polio Eradication Initiative (GPEI) has paused all polio vaccination campaigns.
Routine immunisation, including vaccines against polio, continues in most countries for now, though mainly in fixed facilities with strict guidelines on hygiene and physical distancing. With the expansion of nationwide lockdowns across the developing world it is likely more and more routine immunisation programmes will close temporarily. The suspension of outreach activities, in which health workers visit communities to proactively offer routine vaccinations, is likely to have an immediate impact on vaccine coverage.
Measles outbreaks are currently ongoing in several countries, including the Democratic Republic of the Congo (DRC) and the Central African Republic. The DRC outbreak is currently the world’s largest, affecting over 300,000 people since it started in 2019, with more than 6,000 deaths – nearly three times as many as resulted from the Ebola outbreak in the country.
The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organizations that fund Gavi’s work here.
Vaccines that use harmless viruses as a delivery mechanism are vulnerable to being attacked by our immune system – but experimenting with how they are given could get around this.
A medical professor explains the reasoning behind the delay in the UK and what impact this might have on the vaccine's effectiveness.
COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements.
Some people continue to shed viral RNA for weeks or months after developing COVID-19. Could persistent pockets of infection be to blame?
New review of evidence on a single-dose HPV vaccination schedule is published by PATH-led consortium.
African leaders can make strategies to fight COVID-19 more accessible to the people.
Scientists around the world are working faster than ever to find vaccines that could stop the spread of COVID-19. Now, nearly a year on since the emergence of this new coronavirus, we have several promising vaccines candidates, one of which has…
Immunity to most coronaviruses is short-lived, but will the same hold true for the virus that causes COVID-19 or vaccines against it?